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Mohan GurjarAbstract
Increasing incidence of resistance of gram-negative bacteria against even newer antibiotic including carbapenem
has generated interest in the old antibiotic colistin, which are being used as salvage therapy in the treatment of
multidrug resistant infection. Colistin has excellent bactericidal activity against most gram-negative bacilli. It has
shown persist level in the liver, kidney, heart, and muscle; while it is poorly distributed to the bones, cerebrospinal
fluid, lung parenchyma, and pleural cavity. Being an old drug, colistin was never gone through the drug development
process needed for compliance with competent regulatory authorities that resulted in very much limited understanding
of pharmacokinetic (PK) and pharmacodynamic (PD) parameters, such as Cmax/MIC ratio, AUC/MIC and T >MIC that
could predict the efficacy of colistin. In available PK/PD studies of colistin, mean maximum serum concentration (Cmax) of
colistin were found just above the MIC breakpoint at steady states that would most probably lead to suboptimal for
killing the bacteria, even at dosages of 3.0 million international units (MIU) i.e., 240 mg of colistimethate sodium (CMS)
intravenously every 8 h. These finding stresses to use high loading as well as high maintenance dose of intravenous
colistin. It is not only suboptimal plasma concentration of colistin but also poor lung tissue concentration, which has
been demonstrated in recent studies, poses major concern in using intravenous colistin. Combination therapy mainly
with carbapenems shows synergistic effect. In recent studies, inhaled colistin has been found promising in treatment
of lung infection due to MDR gram-negative bacteria. New evidence shows less toxicity than previously reported.
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Worldwide, there are growing threats to modern medicine
from the emergence of multidrug resistant (MDR) bacteria
causing nosocomial infection. This coupled with marked
decline in the discovery and development of novel anti-
biotics especially against gram-negative bacteria in the last
two decades leads to critical challenge to clinicians. MDR
bacteria are usually defined as when it is resistant to three
or more group of antibiotics. In clinical practice, anti-
biotics commonly used in treating gram-negative infection
are penicillin, cephalosporin, carbapenem, monobactem,
quinolone, and aminoglycoside. Increasing incidence of
resistance of gram-negative bacteria against even newer
antibiotic including carbapenem has been reported in
many countries. In the last few years, with a paucity of
available antibiotic option, interest has been renewed in
the old antibiotic, polymyxins, as salvage therapy in the
management of infections caused by MDR gram-negativeCorrespondence: m.gurjar@rediffmail.com
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unless otherwise stated.pathogens including Pseudomonas, Acinetobacter, Klebsiella,
and Enterobacter species [1-3].
Polymyxins are group of cationic polypeptide antibiotics,
having five different compounds (polymyxin A-E) [4]. In
1949, colistin (Polymyxin E) was first time isolated from
Bacillus polymyxa var. colistinus by Koyama Y. and col-
leagues in Japan (Table 1) [5]. Only polymyxin E (Colistin)
and polymyxin B have been used in clinical practice since
their discovery [1,2]. Both, colistin and polymyxib B, are
produced by the soil bacterium Bacillus spp., and they
differ in structure only by one amino acid at position 6
(-Leu in colistin, while -Phe in polymyxin B) [4].
Clinical experience is more with colistin in comparison
to polymyxin B due to its wider use. After introduction in
clinical practice, uses of parenteral colistin were gradually
waned worldwide within two decades due to reported
severe toxicities, while its topical uses continued [2-4].
So, era of colistin as intravenous use could be divided in
three phases: 1950–1970: against gram-negative infection;
1990–2000: for MDR gram-negative pathogens in cystic
fibrosis; and 2000 onwards: nosocomial infection due
to MDR gram-negative pathogens. In this presentedan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 History of colistin
Year Event
1947 Discovery of polymyxins from bacteria Paenibacillus
polymyxa
1949 Colistin (polymyxin E) was first time isolated from
Bacillus polymyxa var. colistinus by Koyama Y. and
colleagues in Japan
1959 Colistin became available in intravenous formulation
(as colistimethate sodium) for clinical uses
1960s–1970s Colistin used for gram-negative infection; later on,
uses decline due to its toxicities
1990s–2000s Used mainly for lung infection due to MDR
gram-negative pathogens in patients with cystic
fibrosis
2000 onwards Currently in use to treat healthcare-associated MDR
gram-negative infection
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for the use of colistin in lung infection in critically ill
patients without cystic fibrosis.
Review
Current issues in colistin therapy
Colistin, itself is composed of mixture of closely related
components, mainly colistin A (polymyxin E1) and colistin
B (polymyxin E2), which are acylated by (S)-6-methylocta-
noic acid and (S)-6-methylheptanoic acid, respectively
(Figure 1) [4]. Each molecule has a cationic polypeptide
ring with a lipophilic fatty acid chain.Figure 1 Descriptive and chemical structure of colistin. (A) Descriptive
A, (S)-6-methylheptanoic acid for colistin B; Thr threonine, Leu leucine, DabSpectrum of activity
Colistin has excellent bactericidal activity against most
gram-negative bacilli, while no activity against all gram-
positive and most anaerobes (except few like Prevotella
spp., Fusobacterium spp.) organisms (Table 2) [6]. Colis-
tin has also been reported to be potentially active against
several Mycobacterium spp. [7].
Mechanism of action and resistance
The targets site for colistin is lipopolysaccharide (LPS)
component of the outer membrane of gram-negative
bacteria. In there, colistin interacts with the lipid A com-
ponent of the LPS, displacing the calcium and magnesium
bridges that stabilize the LPS, leading to permeabilizing
the bacterial outer membrane that can be described as
detergent-like mechanism of action [4]. Subsequently,
colistin inserted through these cracks in the outer mem-
brane of bacteria causes ‘self-promoted uptake’ as well as
disruption of the integrity of the inner membrane also that
leads to bacterial killing [1,4].
By another postulated mechanism, polycationic poly-
myxin binds to anionic phospholipid; this contact pro-
motes lipid exchange between inner and outer membrane
results in the loss of phospholipid composition leading to
an osmotic imbalance resulting in lytic cell death [4].
The majority of mechanisms of resistance to colistin
are based on modifications to the lipid A portion of LPS
of gram-negative bacteria, like Pseudomonas aeruginosa
and Escherichia coli, that reduces its net negative chargestructure of colistin [*Fatty acid: (S)-6-methyloctanoic acid for colistin
α,γ-diaminobutyric acid]. (B) Chemical structure of colistin.
Table 2 Spectrum of activity of colistin
Gram-negative bacteria
Susceptible Resistant Variable
Gram-negative bacilli: Pseudomonas aeruginosa,
Acinetobacter spp., Escherichia coli, Klebsiella spp.,
Enterobacter spp., Citrobacter spp., Salmonella spp.,
Shigella spp., Haemophilus influenza, Bordetella
pertusis, Legionella pneumophila
Gram-negative bacilli: Proteus spp., Providencia
spp., Morganella morgani, Serratia spp., Edwardsiella
tarda, Burkholderia spp., Brucella spp.
Gram-negative bacilli: Stenotrophomonas
maltophilia, Aeromonas spp., Vibrio spp.
Gram-negative cocci: Neisseria gonorrheae,
Neisseria meningitides, Moraxella catarrhalis
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charged colistin molecule [1,4]. While in Klebsiella pneu-
moniae, the mechanism of resistance to colistin is because
of increased production of capsule polysaccharide [8].
Susceptibility test and heteroresistance
Antimicrobial susceptibility testing for colistin can be
performed using either diffusion (disc diffusion, prediffu-
sion test, or epsilometer test (E-test) or dilution tech-
niques (broth microdilution or agar dilution) [6]. Colistin
sulfate is recommended in susceptibility testing instead of
colistimethate sodium (CMS) [2,6]. The reason for not
using CMS in susceptibility testing, which is used clinic-
ally (see below), is an inactive pro-drug and also undergo
variable hydrolysis resulting in differential killing charac-
teristics and varying susceptibility report. There is another
issue that colistin has, that because of its large molecule, it
diffuses inadequately into the medium which makes disc
diffusion test as a poor performer in susceptibility test.
Among all these methods, broth microdilution and agar
dilution methods are considered as reference methods
[6,9]. Alternatively, E-test method is a reliable, easy to per-
form, and less time-consuming [6].
The breakpoints for colistin susceptibility are defined
differently by two main societies: as per US Clinical and
Laboratory Standards Institution (CLSI), ≤2 mg/L as the
susceptibility breakpoint and >2 mg/L as the resistance
breakpoint, while as per British Society for Antimicro-
bial Chemotherapy (BSAC), ≤4 mg/L as susceptible
and ≥8 mg/L as resistant [2].Table 3 Comparison of two different salts of colistin
Colistimethate sodium






Anti-microbial activity Non-active prodrug: 32 different products
Available for Parenteral use, inhalation useIn a population analysis, profiles of ‘colistin-suscep-
tible’ clinical isolates Acinetobacter baumannii showed
that subpopulation <0.1% bacteria grew in the presence
of colistin 3 to 10 μg/ml, where minimum inhibitory
concentration (MIC) of colistin against all isolates were
within 0.25 to 2 μg/ml [10]. This represents the hetero-
geneous colistin-resistant in colistin-susceptible clinical
isolates called ‘heteroresistance’. This heteroresistance is
observed more frequently in MDR A. baumannii and less
in MDR P. aeruginosa. This heteroresistance phenomenon
explains the substantial regrowth of A. baumannii oc-
curring at 24 h even at colistin concentrations up to
64 × MIC [10]. This heteroresistance also suggests that
colistin monotherapy and extended interval dosage regi-
mens may be problematic especially during treatment of
A. baumannii.
Commercially available forms
Commercially, there are two available forms of colistin
(Table 3): colistin sulfate for oral and topical use and
CMS for parenteral use, as it is less toxic than colistin
sulfate [1-3].
Colistimethate sodium, available as dry powder for
reconstitution before administration, is marketed differ-
ently with respect to the content in the vial as well as rec-
ommended dose. Few brands (Colomycin, Coly-Monas,
Xylistin) labeled the content as international unit, IU, (0.5,
1, or 2 million international units (MIU) per vial), while
other (Coly-Mycin M) labeled the content as mg of colis-
tin base activity (150 mg per vial) [2]. So, the clinician andColistin sulfate







Oral and topical use, inhalation use
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crepancy as regards to dose content per vial by different
brands, and prescription/description should be very much
clear about dose as mg or IU of either CMS or colistin
base activity.
Colistin activity equivalent
1 mg of CMS = 0.375 mg of colistin base activity =
12,500 IU
1 mg of colistin base activity = 2.6 mg of CMS =
32,500 IU
Pharmacokinetic/pharmacodynamic and optimal dosing
of intravenous colistin
CMS as not being stable both in vivo and vitro is hy-
drolysed to many derivatives including colistin and
also makes it difficult to measure accurately both CMS
and colistin in biological samples [2]. Available litera-
ture till now are not much clear about pharmacokinet-
ics of colistin, especially in patient with various degrees
of renal impairment [11]. Absorption from oral mucosa or
gastrointestinal tract does not occur. After parenteral
administration, colistin achieves low protein binding, ap-
proximately 50%. About two thirds of CMS is eliminated
as unchanged mainly by the renal route within 24 h [1,2].
On the other hand, elimination of colistin is non-renal
and non-biliary route by unknown mechanism [2,11]. It
has shown persist level in the liver, kidney, heart, and
muscle, while it is poorly distributed to the bones,
cerebrospinal fluid, lung parenchyma, and pleural
cavity [1-3,11].
In most of the published literature, intravenous colistin
were used in doses of 2.5 to 5.0 mg/kg/day in two to
four divided doses in patients with normal renal function
and also without clear mentioning of drug used in mg of
either CMS or colistin base activity. Being an old drug,
colistin was never gone through the drug development
process needed for compliance with competent regulatory
authorities that resulted in very much limited understand-
ing of PK and PD parameters, such as Cmax/MIC ratio,
AUC/MIC, and T >MIC that could predict the efficacy
of colistin [2,11]. Recent studies started to reveal about
PK/PD of colistin and also demonstrate that it has poor
postantibiotic effect (PAE) [11].
In PK/PD studies of colistin, mean maximum serum
concentration (Cmax) of colistin were found just above
the MIC breakpoint of 2 mg/L (Clinical and Laboratory
Standards Institute) at steady states that would most
probably lead to suboptimal for killing the bacteria, even
at dosages of 3.0 MIU i.e., 240 mg of CMS intravenously
every 8 h [12-14]. Steady state concentration was
achieved at least after 48 h of starting the intravenous
colistin [12]. In a population of critically ill patients
where pharmacokinetic analysis of colistin was done
after intravenous administration, Plachouras et al.predicted that plasma colistin concentration on the basis
of the model developed for different dosage regimen re-
vealed that loading dose of 9 or 12 MIU of CMS as infu-
sion of 15 min or 2 h with maintenance dose of 4.5 MIU
CMS every 12 h achieves rapid (<12 h) and higher plasma
colistin in comparison to dosing regimen 3 MIU as a 15-
min infusion of CMS every 8 h, where it takes about 48 h
to reach 2 mg/L [14]. Daikos et al. also studied the three
different daily doses of CMS (3 MIU every 8 h, 4.5 MIU
every 12 h, and 9 MIU every 24 h) that achieved mean
serum concentration (Cmax) of colistin 3.34, 2.98, and
5.63 μg/ml, respectively, and found that all serum samples
containing colistin >4 μg/ml killed P. aeruginosa, whereas
only 40% of samples containing colistin <4 μg/ml results
in complete eradication of P. aeruginosa (having MIC
1 μg/ml) [13]. But at present, studies evaluating clinical
outcome with these high dosage of colistin are lacking.
In a recent study of PK/PD of colistin, 2 MIU every
8 h, in critically ill patients, Karnik ND et al. observed
that the mean (range) of the maximum plasma drug con-
centration/minimum inhibitory concentration (Cmax/MIC)
ratio for Acinetobacter spp. was 26.3 (0.9–64.9) at steady
state, while for Pseudomonas spp., it was 3.82 (2.3–10.9)
[15]. This shows that an optimum value of the Cmax/MIC
ratio of >8 was achieved against Acinetobacter, not for
Pseudomonas. Bergen et al. examined the PK/PD relation-
ship of colistin against P. aeruginosa and found that colis-
tin efficacy against P. aeruginosa was best correlated with
the AUC/MIC ratio of total and unbound colistin rather
than the Cmax/MIC ratio [16].
It is not only the optimal plasma concentration but
the site of infection also defines the optimal antimicro-
bial therapy. Interestingly, in a study, Imberti et al. found
undetectable level of colistin in broncho-alveolar lavage
fluid of critically ill patients at steady state mean plasma
colistin maximum concentration of 2.21 μg/ml after the
intravenous administration of CMS 2 MIU every 8 h for
at least 2 days [17].
Use in patients with renal dysfunction
Despite colistin is eliminated by non-renal route, dose
adjustment for renal dysfunction is necessary, as there is
reduced renal dependent elimination of its pro-drug
CMS which ultimately lead to increased colistin level
[2,11]. Despite scarcity of studies of PK/PD of colistin
in patients with renal failure, recent recommended
doses are [2]:
Serum creatinine level 1.3–1.5 mg/dl: 2 MIU (160 mg)
of CMS every 8 h
Serum creatinine level 1.6–2.5 mg/dl: 2 MIU (160 mg)
of CMS every 12 h
Serum creatinine level ≥2.6 mg/dl: 2 MIU (160 mg) of
CMS every 24 h
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2 MIU (160 mg) of CMS after each hemodialysis
2 MIU (160 mg) of CMS daily during peritoneal
dialysis
In a study about pharmacokinetics of colistin in critic-
ally ill patients receiving continuous venovenous hemo-
diafiltration (CRRT), Karvanen M et al. suggested that
dose regimen of 2 MIU CMS every 8 h is inadequate
[18]. In another recently published study, Honore et al.
postulate from their experience that patients undergoing
CRRT may receive substantially higher doses of colistin,
i.e., high loading dose followed by a maintenance dose of
up to 4.5 MIU every 8 h because the drug is continu-
ously filtered and also significantly adsorbed in the bulk
of the dialysis membrane [19].
Inhaled colistin
For aerosol inhalation purpose, both forms of colistin
(colistin sulfate and CMS) could be used [2,3]. Colistin,
in the same intravenous formulation, is dissolved in
4–6 ml of normal saline or sterile water to deliver
through nebulizer, though this is not approved by the
Food and Drug Administration (FDA) [20,21]. There
are few studies on the PK of colistin after inhalation.
Ratjen et al. evaluated the colistin pharmacokinetics
postinhalation in patients with cystic fibrosis [22].
This study finds that a single dose of CMS (2 MIU)
achieve significant higher drug concentration in the
sputum even after 12 h with low level in serum and
urine. In another experimental study done by Lu et al.
where pneumonia caused by P. aeruginosa in piglets
and CMS was administered either by nebulization every
12 h or intravenous every 8 h, lung tissue concentration of
colistin was measured [23]. Colistin was found undetected
in the lung tissue after intravenous infusion, while after
nebulization, peak lung tissue concentrations were signifi-
cantly higher in the lung segments (more in mild pneu-
monia segments and less in severe pneumonia area,
median 10.0 versus 1.2 μg/g).
As per drug package insert information, the recom-
mended doses of colistin when given by inhalation are as
below [24]:
Body weight <40 kg: 0.5 MIU (40 mg) of CMS every 12 h
Body weight >40 kg: 1.0 MIU (80 mg) of CMS every 12 h
For recurrent or severe pulmonary infection: 2.0 MIU
(160 mg) of CMS every 8 h
Optimal inhalation therapy also requires consideration
of several factors like the type of nebulizer, aerosol particle
size, position of patient, severity of airway obstruction, etc.
In a mechanically ventilated patient, there are factorsmore than this, i.e., artificial airway size, humidity, gas
density, tidal volume, nebulization cycling during inspir-
ation versus continuous, etc., which may affect drug
delivery at the target site [25].
Combined therapy with other antibiotics and synergism
In clinical practice, colistin is frequently used as combin-
ation therapy, though there is scarcity of data that whether
combination therapy is superior to monotherapy. One of
the reasons for limited studies may be using this drug in
treating MDR pathogens that deterred the clinician from
providing colistin as a monotherapy. In a recent review by
Petrosillo et al. on colistin monotherapy versus combin-
ation therapy in animal and clinical studies, they revealed
that synergistic effect was detected in all the nine studies
examining the combination of colistin and rifampicin,
whereas carbapenems exhibited a synergistic effect in two
out of three studies [26]. Colistin combined with tigecyc-
line did not show good synergistic action [27]. Consider-
able synergy was found between levofloxacin and colistin
in a recently published study [28]. Pankuch et al. studied
time killing synergy with subinhibitory concentration of
meropenem and colistin and found significant synergy
against A. baumannii at 6, 12, and 24 h, while there was
no significant synergy against P. aeruginosa at any point
of time [29]. In another in vitro study by Souli et al.,
the combination of imipenem (irrespective of MIC)
and colistin against K. pneumoniae showed synergistic
activity against isolates susceptible either to both
agents or to colistin, while rarely synergistic against
non-colistin-susceptible strains [30]. A recently published
study by Leu et al. showed that the synergy of imipenem
and colistin against imipenem-non-susceptible multi-drug
resistant A. baumannii was significantly better for the co-
listin concentration at 1 mg/L than that at 0.5 mg/L [31].
Toxicity
Two types of toxicity, namely, nephrotoxicity and neuro-
toxicity has been reported with the uses of colistin. A
systematic review of the toxicity of polymyxin revealed
that in the old literature, incidences of both toxicities
were reported to be considerably high, while new evi-
dence shows less toxicity than previously reported [32].
The observed nephrotoxicity was as high as 50% in old
studies versus 15%–25% in recent studies, although the
definition of nephrotoxicity was not standardized be-
tween the studies [32]. Renal toxicity of colistin has been
described as dose dependent and may be partly due to
their D-amino acid content and fatty acid component
that leads to acute tubular necrosis. Renal toxicity from
colistin has been found apparently less than the use of
polymyxin B [32]. Age (more than 60 years) has also
been found as a significant risk for colistin-induced
nephrotoxicity [33]. The concurrent administration of
Gurjar Journal of Intensive Care  (2015) 3:3 Page 6 of 12nephrotoxic drugs, hypovolemia or shock, and severity
of illness may increase the likelihood of development
of acute kidney injury (AKI).
In a recent preliminary study on high-dose colistin
(9 MIU twice-daily), administration in critically ill pa-
tients found that AKI developed during 18% of treatment
courses did not require renal replacement therapy (RRT)
and subsided within 10 days from colistin discontinuation
[34]. Also, there was no correlation between variations in
serum creatinine level and daily and cumulative doses of
colistin or duration of colistin treatment. In another study,
Dewan et al. also reported AKI in 16% of patients in
whom high dose, extended interval colistin (9 MIU stat
followed by 4.5 MIU 12 hourly) was used, while no patient
required RRT [35].
Overall incidence of neurotoxicity related to colistin
use is less than the nephrotoxicity. Earlier studies reported
paresthesias in about one forth of patients receiving
colistin, with few case reports of neuromuscular block-
ade or apnea, while recent studies did not reported any
significant neurotoxicity [32,36]. Neurotoxicity is also dose
dependent and may be triggered by the presence of risk
factors like the presence of hypoxia, co-administration of
muscle relaxant, narcotics, sedatives, or steroids [32,37,38].
Colistin aerosol inhalation therapy is generally well tol-
erated with few reported side effects like throat irrita-
tion, cough, and bronchospasm, which may be because
of the presence of excipients/preservatives [20].
Colistin for lung infection and clinical outcome
In the last decade, many studies published the use of colis-
tin in the treatment of lung infection in patients without
cystic fibrosis, with conflicting results. Most of the studies
have population of adult ICU patients with MDR VAP,
and types of study were single-arm (Table 4) [11,39-75]. In
a systematic review and meta-regression to know the effi-
cacy of colistin for the treatment of VAP, Florescu et al.
analyzed 6 controlled studies (359 patients) and single-
arm analysis from 14 studies (437 patients) [76]. Among
the six two-arm studies (three prospective including one
RCT and three retrospective studies), which were un-
blinded, the mean duration of intravenous colistin was
11.4 days at a mean dose of 252.5 mg/70 kg/day and
aerosolized colistin was administered for a mean 9.25 days
at a mean dose of 355 mg/70 kg/day. While, in single-arm
studies, intravenous colistin was used for a mean of
15 days at a mean dose of 209.5 mg/70 kg/day and
aerosolized form was given for a mean of 14 days at a
mean dose of 80 mg/70 kg/day. In the meta-analysis of six
controlled studies, there was no significant difference for
overall clinical response between colistin and control
groups (OR 1.14 [95% CI 0.74–1.77; p = 0.56]; I2 = 0%;
Q = 4.98 [p = 0.42]), even after controlling for concomi-
tant antibiotic treatment, or for the dose of intravenouscolistin. Though, there was a trend for better microbio-
logical response. Also, there was no significant difference
between the colistin and control groups with respect to
ICU, hospital, or 28-day mortality. Neither, incidence of
nephrotoxicity was different in both groups; but one study
reported higher incidence for respiratory toxicity [55].
In the meta-analysis of single-arm studies, there was fa-
vorable clinical response with colistin found (95% CI
0.64–0.80; Q = 55.3; p < 0.0001). Also, there was a sig-
nificant microbiological response for aerosolized form,
but not with intravenous form. There was a higher inci-
dence of nephrotoxicity with intravenous administra-
tion, and no patient had neurotoxicity or respiratory
side effects. These single-arm studies also showed mor-
tality benefit (ICU, hospital, as well as 28-day mortality)
in this meta-analysis [76].
In another recently published systematic review and
meta-analysis of colistin for the treatment of VAP caused
by MDR gram-negative bacteria, Gu et al. included 14
studies (published during 2003 to 2013, total 1,167 pa-
tients), 2 were RCTs, 4 were case-control studies, and 8
were cohort studies [77]. In this analysis for use of colis-
tin versus β-lactam antibiotics, they found that there
was no significant difference in both groups for clinical
cure rate (OR = 1, 95% CI 0.68–1.47, p = 0.99, I2 = 0%),
microbiological eradication, ICU mortality, hospital mor-
tality, and nephrotoxicity. While comparing aerosolized
plus intravenous colistin (AS plus IV colistin) versus
intravenous colistin alone, this meta-analysis revealed
that AS plus IV colistin had a higher clinical cure rate
(OR = 2.12, 95% CI 1.40–3.20, p = 0.0004, I2 = 0%), but
there was no significant differences in microbiological
eradication, ICU, and hospital mortality and nephrotox-
icity between both (AS plus IV colistin and intravenous
colistin alone) groups. This meta-analysis also found that
colistin-combined therapy did not have a better clinical
cure, microbilogical eradication, ICU and hospital mor-
tality, or nephrotoxicity, when compared with colistin
monotherapy, for the treatment of MDR gram-negative
VAP [77].
While another systematic review and meta-analysis on
the role of aerosolized colistin in the treatment of VAP,
Valachis et al. included 8 studies (690 patients) and
found a statistically significant improvement in clinical
response as well as microbiological eradication, when AS
colistin was added to the standard antimicrobial therapy
in comparison with patients who received IV colistin
(OR, 1.57; 95% CI, 1.14–2.15; p = 0.006 and OR, 1.61;
95% CI, 1.11–2.35; p = 0.01, respectively) [78]. Overall
mortality was not found to be significantly different be-
tween the two comparative arms (OR, 0.74; 95% CI,
0.54–1.01; p = 0.06). When AS colistin monotherapy was
compared with IV colistin (31 patients, 2 studies), there
was no differences between the two treatment arms for











2003 Prospective No 35 Acinetobacter baumanii IV Spain Garnacho-Montero [39]
2003 Prospective No 18 Pseudomonas aeruginosa IV USA Linden [40]
2003 Prospective No 15 P. aeruginosa, A. baumanii IV Greece Markou [41]
2006 Prospective No 9 P. aeruginosa, A. baumanii IV and AS Greece Falagas [42]
2006 Prospective No 16 A. baumanii AS Morocco Motaouakkil [43]
2007 Retrospective No 120 P. aeruginosa, A. baumanii IV Tunisia Kallel [44]
2007 Retrospective No 61 P. aeruginosa, A. baumanii IV Argentina Rios [45]
2008 Prospective Yes 28 A. baumanii IV Greece Betrosian [46]
2008 Retrospective No 10 A. baumanii IV Korea Song [47]
2008 Prospective No 8 P. aeruginosa IV and AS Greece Mastoraki [48]
2008 Prospective No 19 A. baumanii IV Italy Bassetti [49]
2008 Prospective No 60 P. aeruginosa, A. baumanii, Klebseilla pneumoniae AS Greece Michalopoulos [50]
2008 Prospective No 10 P. aeruginosa, A. baumanii IV Greece Markou [11]
2009 Retrospective No 9 P. aeruginosa, A. baumanii IV Turkey Tasbakan [51]
2009 Retrospective No 41 A. baumanii IV South Korea Jang [52]
2010 Retrospective No 86 P. aeruginosa, A. baumanii, K. pneumoniae IV and AS Greece Kofteridis [53]
2010 Retrospective No 121 P. aeruginosa, A. baumanii, K. pneumoniae IV and AS Greece Korbila [54]
2010 Prospective Yes 100 P. aeruginosa, A. baumanii, K. pneumonia, Escherichia coli AS Thailand Rattanaumpawan [55]
2010 Retrospective No 45 A. baumanii AS Taiwan Lin [56]
2010 Retrospective No 11 P. aeruginosa, A. baumanii, K. pneumonia, Enterobacter cloacae IV Greece Iosifidis [57]
2011 Retrospective No 15 A. baumanii AS Thailand Nakwan [58]
2011 Prospective No 15 A. baumanii IV and AS Spain Perez-Pedrero [59]
2011 Retrospective No 20 P. aeruginosa IV and AS Belgium Naesena [60]
2012 Prospective No 165 P. aeruginosa, A. baumanii AS France Lu [61]
2012 Retrospective No 36 A. baumanii IV Turkey Simsek [62]
2012 Retrospective No 45 A. baumanii IV and AS Turkey Kalin [63]
2013 Retrospective No 98 A. baumanii IV Israel Zalts [64]
2013 Retrospective No 208 P. aeruginosa, A. baumanii, K. pneumonia IV and AS Italy Tumbarello [65]
2013 Prospective Yes 43 A. baumanii IV Turkey Aydemir [66]
2013 Retrospective No 95 P. aeruginosa, A. baumanii, K. pneumonia IV and AS USA Doshi [67]
2013 Retrospective No 49 A. baumanii IV and AS Spain Garnacho-Montero [68]











Table 4 Recent studies on colistin for the treatment of ventilator-associated pneumonia (VAP) (Continued)
2014 Retrospective No 26 A. baumanii AS Taiwan Hsieh [70]
2014 Retrospective No 130 A. baumanii IV Thailand Khawcharoenporn [71]
2014 Retrospective No 118 A. baumanii IV Taiwan Chuang [72]
2014 Retrospective No 141 A. baumanii, P. aeruginosa Enterobacteriaceae IV France Soubirou [73]
2014 Retrospective No 10 A. baumanii AS Korea Choi [74]
2014 Retrospective No 107 P. aeruginosa, A. baumanii IV Italy Petrosillo [75]
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also commented that the quality of evidences for the out-
comes was very low according to the Grading of Recom-
mendations Assessment, Development, and Evaluation
(GRADE) approach [78].
All three meta-analyses of colistin for the treatment of
VAP are summarized in Table 5.
Future roadmap for optimization of the clinical use of
colistin—‘1st International Conference on Polymyxins,’
Prato, Italy, 2013
With the aim of better understanding of the current use
of polymyxins, including factors affecting the safe and
effective use of them, and identify research areas to fill
gaps in existing knowledge, delegates from 27 countries
from various specialties attended ‘The 1st International
Conference on Polymyxins’ held in Prato, Italy, on 2–4
May, 2013. The consensus panel members identify high-
priority issues, some of them are as follows [79]:
▪ Uniformity in expression of the amount of drug in a
parenteral vial by different manufacturers should be
expressed as mg of colistin base activity (CBA) or
number of International Unit (IU)
▪ Uncertainties regarding susceptibility testing and
breakpoints (currently under review jointly by the
Clinical and Laboratory Standards Institute, CLSI and
the European Committee on Antimicrobial
Susceptibility Testing, EUCAST)Table 5 Summary of 3 meta-analysis of colistin for the treatm
Meta-analysis Outcome
Clinical cure Microb
A. Florescu et al. [76]
Colistin versus control
group
Not significant; 6 two-arm studies,
359 patients (OR 1.14 [95% CI 0.74–1.77;




Single-arm studies Significant; 13 studies, 429 patients
(95% CI 0.64–0.80; Q = 55.3; p < 0.0001)
Significa
CI 0.44–
B. Gu et al. [77]
Colistin versus β-Lactam
antibiotics
Not significant; 6 studies, 507 patients





AS + IV colistin versus
IV colistin alone
Significant; 3 studies, 415 patients







Not significant; 5 studies, 245 patients





C. Valachis et al. [78]
Adjunctive AS colistin
versus IV colistin
Significant; 8 studies, 690 patients





Not significant; 2 studies, 31 patients Not sign
AS aerosolized, IV intravenous.▪ Need of therapeutic drug monitoring in routine
clinical practice (to maximize bacterial killing and
minimize side effects in individual patients)
▪ Suggested research areas are prospective studies using
therapeutic drug monitoring, pharmacokinetic studies
in special patient populations, combination versus
monotherapy, aerosol drug delivery alone, or in
combination with intravenous route for the treatment
of pneumonia
Conclusions
In recent time, the uses of colistin to treat lung infection
due to MDR gram-negative bacteria have been increased
throughout the world, with little understanding of PK/PD
of colistin. The usual dose of 3 MIU of colistin every 8 h
intravenously achieves plasma colistin concentration just
above the MIC level, and it took at least 48 h to reach the
steady plasma colistin level. These finding stresses to use
high loading (9 or 12 MIU of CMS) as well as high main-
tenance dose (4.5 MIU every 12 h or 9 MIU of CMS every
24 h) of intravenous colistin, but there is scarcity of clin-
ical studies with these doses. Using colistin with carbapen-
ems has been found to have a synergistic action, though
there is no strong evidence for using colistin/carbapenem
combination therapy. On the other side, having PAE and
heteroresistance phenomenon, especially for Acinetobacter
infection, small-interval doses regimens of colistin may
have better efficacy and reduces the chance of develop-
ment of resistant against colistin. Currently, availableent of ventilator-associated pneumonia
iological eradication ICU mortality
ificant; 2 studies, 128 patients
7 [95% CI 0.97–4.12; p = 0.06];
%; Q = 1.03 [p = 0.31])
Not significant; 2 studies, 155 patients
(OR 1.27 [95% CI 0.66–2.43; p = 0.47];
I2 = 0%; Q = 0.057 [p = 0.81])
nt; 9 studies, 267 patients (95%
0.79; Q = 121.56; p < 0.0001)
Significant; 5 studies, 257 patients (95%
CI 0.15–0.42; Q = 43.61; p < 0.0001)
ificant; 3 studies, 91 patients
64, 95% CI 0.18–2.22, p = 0.48,
)
Not significant; 3 studies, 320 patients;
(OR = 1.02, 95% CI 0.60–1.72, p = 0.95,
I2 = 0%)
ificant; 2 studies, 242 patients
29, 95% CI 0.63–2.63, p = 0.48,
)
Not significant; 3 studies, 415 patients
(OR = 0.75, 95% CI 0.50–1.11, p = 0.15,
I2 = 0%)
ificant; 4 studies, 212 patients
49, 95% CI 0.79–2.83, p = 0.22,
Not significant; 2 studies, 123 patients
(OR = 0.48, 95% CI 0.22–1.03, p = 0.06,
I2 = 0%)
nt; 7 studies, 479 patients
1; 95%CI, 1.11–2.35; p = 0.01)
Not significant; 7 studies, 668 patients
(OR, 0.74; 95%CI, 0.54–1.01; p = 0.06)
ificant; 2 studies, 31 patients -
Gurjar Journal of Intensive Care  (2015) 3:3 Page 10 of 12evidences throw highlight that different doses and/or
dose intervals may be required for different types of
gram-negative infections and warrant further studies
for better understanding about PK/PD of colistin and its
clinical applications. It is not only suboptimal plasma
concentration of colistin but also poor lung tissue
concentration, which has been demonstrated in recent
studies, poses major concern in using intravenous colistin.
Inhaled colistin as an adjunct treatment for lung infection
due to MDR gram-negative bacteria have been found
promising in recent studies as well as in meta-analysis.
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